Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
주식 순위
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
주가
$4.87
시가총액
$4.36B
변동 (1일)
-5.47%
변동 (1년)
-15.62%
국가
CN
거래 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
카테고리
Healthcare
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 3.43
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 3.43입니다. 2024년 말 기준 P/B 비율은 2.38였습니다.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd의 P/B 비율 기록 (2006 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 3.43 | 14.17% |
| 2025 | 3.00 | 26.18% |
| 2024 | 2.38 | -14.98% |
| 2023 | 2.80 | 64.60% |
| 2022 | 1.70 | -30.89% |
| 2021 | 2.46 | -23.58% |
| 2020 | 3.22 | -68.02% |
| 2019 | 10.06 | 16.65% |
| 2018 | 8.62 | -11.20% |
| 2017 | 9.71 | -12.75% |
| 2016 | 11.13 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | -100.00% |
| 2012 | 19.13 | -19.19% |
| 2011 | 23.67 | -9.19% |
| 2010 | 26.07 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.6964 | 95.50% |
US
|
|
| 13.6307 | 297.95% |
US
|
|
| 4.4521 | 29.98% |
AU
|
|
| 4.2241 | 23.32% |
BE
|
|
| 6.3632 | 85.78% |
NL
|
